The prevalence and diagnostic utility of bronchodilator responsiveness (BDR) in a real-life setting is unclear. Objective: To explore this uncertainty
The diagnosis of COPD requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context.
The COPD Foundation is kicking off its 20th anniversary year with exciting news! Bronchiectasis and NTM 360, a division of the COPD Foundation, is thrilled to announce its journey to establish a Bronchiectasis and NTM Care Center Network.
El 23 y 24 de febrero de 2024 se celebra la 11ª Edición Barcelona Boston Lung Conference. Presentación de 12 abstracts de entre todos los abstracts recibidos.
The GOLD 2023 report identifies different causes (etiotypes) of COPD. Their prevalence in individuals in the general population with persistent airflow obstruction (PAO) is unknown.
In this expert interview, MeiLan K Han and Alvar Agustí discuss the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 executive report, which proposes a new definition for COPD and covers the latest updates in its diagnosis, management, and prevention.
Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide. While tobacco smoking is a key risk factor, COPD also occurs in never-smokers (NS).
Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. (…)
Un año después de su presentación en sociedad, el programa ANTES está en pleno desarrollo. En línea con sus objetivos iniciales, muy recientemente se ha publicado un artículo especial enfatizando la importancia de realizar ensayos clínicos de intervención en pacientes jóvenes con EPOC o pre-EPOC19. .
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime…
